Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846343 | 0.84 | HIF1A (0.56) | LMNANPC1POLBRAB9ASRC | |
| SCHEMBL10133069 | 0.83 | SRC (0.67) | LMNAPOLBRAB9ASRCHIF1A | |
| SCHEMBL31540432 | 0.80 | HDAC1 (0.48) | LMNANPC1POLBRAB9ASRC | |
| SCHEMBL17091406 | 0.78 | CLK1 (0.47) | — | |
| SCHEMBL4167565 | 0.78 | RAB9A (0.57) | LMNANPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL19555318 | 0.77 | ESR1 (0.41) | LMNANPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL22581561 | 0.77 | ADORA2A (0.47) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11917561 | 0.77 | LMNA (0.55) | LMNARAB9ASRCHIF1ALIPG | |
| SCHEMBL18041383 | 0.77 | FTO (0.42) | LMNANPC1POLBRAB9AHIF1A | |
| SCHEMBL31380221 | 0.77 | SRC (0.79) | LMNAPOLBSRCLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2251324-A1 | HETEROARYL-ALKYLCARBAMATE COMPOUNDS AND THEIR USE AS INHIBITORS OF THE FAAH ENZYME | Sanofi-Aventis (FR) | 2010-11-17 | — | — | EP | disclosed |
| US-20100069405-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | US | disclosed |
| US-7645757-B2 | Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors | SANOFI-AVENTIS (FR) | 2010-01-12 | — | — | US | disclosed |
| EP-1720829-B1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-10-14 | — | — | EP | disclosed |
| US-20070021426-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069405-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR1 | LMNA 2092/4885NPC1 526/4885POLB 2741/4885 |
| US-20070021426-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | LMNA 1471/4885NPC1 992/4885POLB 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.